Experimental AATD drug study halted early
Disease control
Terminated
This study tested a new drug called KRRO 110 in healthy volunteers and people with Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can damage the lungs and liver. The goal was to check safety and how the drug moves through the body. The study was stopped early, an…
Phase: PHASE1, PHASE2 • Sponsor: Korro Bio, Inc. • Aim: Disease control
Last updated May 26, 2026 08:34 UTC